Vericel Corporation 2017 Form 10-K Summary
Business context and reporting period
Vericel is a commercial-stage cell therapy company focused on sports medicine and severe burn care. The filing covers the fiscal year ended December 31, 2017, including fourth-quarter results. U.S. marketed products were MACI, an autologous cartilage-repair product, and Epicel, a cultured epidermal autograft for severe burns. MACI launched in January 2017 and replaced Carticel, which was withdrawn from the U.S. market at the end of the second quarter.
The company also continued development of ixmyelocel-T for advanced heart failure. Following FDA feedback in September 2017 that at least one additional Phase 3 study would be required, Vericel stated that it would not independently fund such a trial and was seeking a development partner.
Key financial metrics
| Metric | 2017 | 2016 | Change |
|---|---|---|---|
| Total revenue | $63.9 million | $54.4 million | +17.5% |
| Product sales | $62.8 million | $54.4 million | +15.4% |
| MACI and Carticel revenue | $43.9 million | $38.9 million | +13.0% |
| Epicel revenue | $18.9 million | $15.5 million | +21.6% |
| License revenue | $1.2 million | — | New in 2017 |
| Gross profit | $33.6 million | $26.1 million | +28.7% |
| Gross margin | 52.5% | 47.9% | +460 bps |
| Operating loss | $15.0 million | $19.2 million | Improved by $4.3 million |
| Net loss | $17.3 million | $19.6 million | Improved by $2.3 million |
| Basic and diluted loss per share | $0.52 | $1.18 | Improved |
| Cash flow from operations | $(13.2) million | $(19.9) million | Improved by $6.7 million |
Fourth-quarter 2017 revenue was $23.4 million, gross profit was $15.0 million, operating income was $1.2 million, and net income was $0.3 million, compared with a fourth-quarter 2016 net loss of $6.2 million. Fourth-quarter performance benefited from seasonal demand and increased product volume.
Year-end cash was $26.9 million, compared with $23.0 million at December 31, 2016. Working capital was $37.4 million, total assets were $54.6 million, and total liabilities were $32.0 million. Accounts receivable were $18.3 million and inventory was $3.8 million.
Debt and liquidity
- In December 2017, Vericel refinanced its credit facilities with a $15.0 million term loan and access to a revolving line of credit of up to $10.0 million.
- Outstanding debt at year-end was $17.5 million, consisting of $15.0 million under the term loan and $2.5 million under the revolver. Remaining revolver capacity was $7.5 million.
- The weighted-average interest rate was 8.32%, plus a 3.6% final payment on the term loan at maturity. The term loan matures in December 2021 after an interest-only period through December 1, 2018.
- The facility includes minimum revenue covenants and a subjective material-adverse-change acceleration clause. The December 31, 2018 minimum revenue covenant is $63.6 million, and the company reported compliance at year-end.
- Management believed cash, operating resources, and available credit were sufficient to support operations through at least March 31, 2019, but warned that additional capital could be required if results differ from projections or debt covenants are not met.
Material changes versus the prior comparable period
- MACI became the primary cartilage product following its January 2017 launch and Carticel’s withdrawal in the second quarter.
- MACI and Epicel sales increased, while higher utilization and a largely fixed manufacturing cost base drove gross margin expansion to 52.5% from 47.9%.
- Research and development expense decreased to $12.9 million from $15.3 million, primarily because ixmyelocel-T spending declined after Vericel decided not to pursue a Phase 3 trial independently. MACI development spending increased.
- Selling, general and administrative expense increased to $35.6 million from $27.4 million, driven by sales-force expansion, MACI marketing, and reimbursement and patient-support activities.
- The 2016 $2.6 million impairment charge for Carticel-related commercial rights did not recur in 2017.
- Vericel entered into an Asian license agreement with Innovative Cellular Therapeutics. It recognized $1.2 million of license revenue and received $5.2 million gross, including $4.0 million allocated to a warrant that was subsequently exercised for 816,850 common shares.
- The company sold 1,983,023 shares under its at-the-market program for $7.2 million of net proceeds during 2017; approximately $16.7 million of capacity remained at year-end.
Guidance, outlook, commentary, and unusual items
- Management’s strategy is to grow MACI adoption among sports-medicine surgeons, expand Epicel use among burn centers, reduce marginal manufacturing costs through scale, and achieve positive operating income by keeping commercial-expense growth below revenue growth.
- Management expects continued quarterly volatility. MACI revenue is typically stronger in the second and fourth quarters, while Epicel demand is generally higher during colder months, although Epicel patient volume can vary substantially.
- Revenue estimates were affected by a reimbursement dispute involving Vital Care and a third-party payer. Vericel initially reduced revenue allowances by $2.8 million, including $2.1 million related to 2016 sales and $0.7 million related to 2017 sales, then recognized a $1.4 million favorable adjustment after the dispute was resolved.
- Orsini became the specialty pharmacy distributor for MACI in May 2017. Orsini represented 35% of Carticel and MACI revenue and 46% of accounts receivable concentration for 2017, creating customer and collection concentration risk.
- The company recognized a $0.9 million loss on extinguishment of debt in connection with the December refinancing. It also recorded a $0.3 million non-cash increase in warrant liabilities and $2.7 million of stock-based compensation expense.
- The European manufacturing authorization for MACI was expected to expire at the end of June 2018 because Vericel did not plan to establish an EU-compliant manufacturing facility.
- Key risks include continued operating losses, dependence on a single Cambridge manufacturing facility, reimbursement uncertainty, reliance on suppliers including a sole supplier for the MACI membrane, regulatory compliance, manufacturing scale-up, competition, customer concentration, and potential dilution from future equity financing.
Most important facts for investors to verify
- Whether MACI adoption and Epicel utilization continue to support revenue growth and gross-margin expansion.
- Whether Vericel achieves sustained operating profitability before cash resources become constrained.
- Compliance with the $63.6 million trailing-twelve-month revenue covenant and the potential for debt acceleration.
- Cash-burn trends, remaining ATM capacity, and the need for additional debt or equity financing.
- Collection and reimbursement performance following the Vital Care dispute and the transition to Orsini.
- Concentration of U.S. commercial manufacturing in the Cambridge facility and dependence on single-source suppliers.
- Progress, if any, toward partnering ixmyelocel-T for the required Phase 3 development program.
- The effects of the pending European MACI authorization expiration and the company’s ability to expand internationally through the ICT license.